EDUCATION > Educational Programs > E-Learning > Videos/Webcasts > Castration-Resistant Prostate Cancer Webcast

CRPC Guideline Panel Discussion Video

Support provided by educational grants from the following companies:

Abbvie Algeta Astellas Scientific and Medical Affairs, Inc.
Bayer HealthCare Pharmaceuticals Janssen Biotech, Inc. Medivation, Inc.

We would like to sincerely thank these supporters for providing the funding to support the promotion and distribution of this activity. Consistent with the AUA strict conflict of interest policy, these supporters had no access to the AUA guidelines panels, played no part in the research or development of AUA guidelines and did not review them prior to publication. The support offered, and gratefully accepted by the AUA, sincerely was in the best interest of the educational mission of the guidelines to help you and your practice.

Program Description and Objectives

The purpose of this program is to provide urologists with practical knowledge that will allow them to respond effectively to the needs to patients with Castration Resistant Prostate Cancer.

Learning Objectives

After participating in this activity, participants should be able to:

  • Demonstrate an enhanced understanding of metastatic castrate resistant prostate cancer
  • Evaluate the spectrum of castration resistant prostate cancer, from patients with mild PSA elevation with no symptoms to patients who are highly symptomatic with few options for treatment outside of palliative care
  • Compare the variety of FDA approved treatments available for the treatment of metastatic castration resistant prostate cancer, while assessing the evolution of treatment options from palliative care to drug therapies
  • Analyze the most common clinical scenarios of metastatic castration resistant prostate cancer, identified in clinical practice, as outlined in the six index patients

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This enduring material is designed for practicing urologic physicians, American Board of Urology (ABU) candidates and/or residents.

Method of physician participation in the learning process

To claim CME credit/hours of participation for the webcast, the learner must view the webcast, complete the posttest, passing with 80% accuracy and submit the evaluation.

Disclaimer

All data concerning results of the study program are strictly confidential and security measures have been set up at the AUA to ensure that only the individual participant has access to his/her scores.

Media Used

Online

  • Minimum Hardware and Software Requirements
  • PC-compatible computer running Windows XP
  • Macintosh computer running OS X 10.1 or later
  • Linux computer capable of running Mozilla Firefox 3.0 or later
  • Processor speed of 800 MHz (1GHz preferred)
  • 128 MB of RAM (more preferred)
  • Modem speed of at least 56k (broadband preferred).
  • Internet browser (Internet Explorer 8.0 or later, Firefox 3.0 or later, Chrome 4.0 or later, or Safari 4.0 or later)
  • Adobe Acrobat Reader 9 or newer.

Estimated time to complete each lesson

0.5 hour

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/ or Education Content Review Committee or its subgroup
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point- counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Disclosures

Michael S. Cookson, MD, MMHC
Chairman and Professor
Donald D. Albers Endowed Chair
Urologic Oncology
University of Oklahoma
Disclosures: Endo: Consultant or Advisor, Scientific Study or Trial; Spectrum: Consultant or Advisor; GE Healthcare: Consultant or Advisor, Scientific Study or Trial; Myriad: Consultant or Advisor; US HIFU: Consultant or Advisor; Covidien: Consultant or Advisor, Scientific Study or Trial; Photocure: Meeting Participant or Lecturer; Myriad: Consultant or Advisor

Adam Stuart Kibel, MD
Assistant Professor
Harvard Medical School
Disclosures: Dendreon: Consultant or Advisor, Meeting Participant or Lecturer; Sanofi-Aventis: Consultant or Advisor, Scientific Study or Trial; National Cancer Institute: Consultant or Advisor; Specrum: Consultant or Advisor; Myriad Genetics: Consultant or Advisor

Stephen J. Freedland, MD
Assistant Professor
Duke University
Disclosures: AstraZeneca: Consultant or Advisor, Meeting Participant or Lecturer , Other: None; Amgen: Consultant or Advisor; GSK: Scientific Study or Trial; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Medivation: Consultant or Advisor; Amgen: Other: None; Janssen: Consultant or Advisor, Scientific Study or Trial; Centocor Ortho Biotech: Other: None; Bayer: Consultant or Advisor; Mitomics: Consultant or Advisor; Astellas: Consultant or Advisor

Abid Khan
Nothing to disclose

Michael A. Folmer
Nothing to disclose

Planner Disclosures

Elspeth M. McDougall, MD, FRCSC, MHPE
Chair, Office of Education
American Urological Association
Disclosures: Ethicon Endo-surgery: Other; Karl Storz Endoscopy America: Other

J. Kellogg Parsons, MD, MHS, FACS
Associate Professor
Department of Urology
Moores Comprehensive Cancer Center
University of California, San Diego Health System
Disclosures: AMS: Meeting Participant or Lecturer; Sophiris: Consultant or Advisor; Watson: Consultant or Advisor

Evidence-based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors, and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Acknowledgement For Support:

Support provided by educational grants from the following companies:

AbbVie
Algeta US
Astellas Scientific and Medical Affairs, Inc.
Bayer HealthCare Pharmaceuticals
Janssen Biotech, Inc.
Medivation, Inc.

System Requirements for Online Test

A PC-compatible computer running Windows XP, or a Macintosh computer running OS X 10.1 or later. Internet access. Adobe Acrobat Reader 9 or newer.

Release Date

Feburary 2014
Expiration Date: February 2017
Copyright © 2014 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.

AUA Privacy and Confidentiality Policy

www.AUAnet.org/cme/onlineeduconf.cfm
Email cme@AUAnet.org or hstudy@AUAnet.org with any questions

It is recommended this video be viewed in full screen.

Credit Designation: The American Urological Association Education and Research, Inc designate this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Status
Module 1 Lesson 1 Posttest Available 0.50 credits/hours

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT